A growing body of evidence suggests that GLP-1R agonists may be protective in multiple neurodegenerative diseases including glaucoma (Bertilsson et al., 2008; Harkavyi et al., 2008; Kim et al., 2009; Li et al., 2009; Erbil et al., 2019; Park et al., 2021; Sterling et al., 2021). Here, GLP1R is linked to neurodegenerative disease.